Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Refixia

- PMLiVE

Novo Nordisk plans $2bn expansion of its diabetes facilities

Comes as the Danish firm prepares to move oral semaglutideinto phase III trials

- PMLiVE

Novo Nordisk’s Victoza fails type 1 diabetes trial

Danish firm’s hopes dashed by latest data

Sanofi reception

Sanofi keeps Toujeo price level with Lantus in UK

French firm hoping to maintain market share with its next-gen insulin product

- PMLiVE

Novo Nordisk’s next-gen GLP-1 aces late-stage trial

Firm hopes semaglutide will shore up future sales of its diabetes range

- PMLiVE

Novo pulls Tresiba from Europe’s biggest market

Firm’s new insulin will not be sold in Germany

- PMLiVE

Tantalising data for Baxter spin-off’s haemophilia therapy

Early-stage testing shows promise as a potentially transformative treatment

- PMLiVE

Novo Nordisk becomes diabetes drug sales leader

Supplants former frontrunner Sanofi - but both firms set for a tough 2015

- PMLiVE

Rivals look to put pressure on Sanofi’s Lantus

Novo Nordisk and Lilly claim clinical benefitsover top-selling diabetes drug

- PMLiVE

Novo brings Xultophy to third European market

Launches diabetes combination of Tresiba-Victoza in the UK

- PMLiVE

IQWiG unimpressed with Tresiba for children

German cost watchdog says Novo’s insulin may in fact cause more harm in certain patients

- PMLiVE

Sobi launches disease awareness app with UK hospital

Pharma firm links with GOSH on helping children with haemophilia

- PMLiVE

Novo Nordisk appoints Liz Skrbkova

She moves from the pharma company's UK operations for a new role in Denmark

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links